Cardiol Therapeutics share price logo

Cardiol Therapeutics

NASDAQ: CRDL

Small Cap

$2.21

+0.01

(+0.68%)

as on

Cardiol Therapeutics Stock Performance

as on September 9, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $2.16
    $2.24
    downward going graph

    2.26%

    Downside

    1.36%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.88
    $2.28
    downward going graph

    60.18%

    Downside

    2.94%

    Upside

    downward going graph

Cardiol Therapeutics share price movements today

Previous Close
$2.20
Open
$2.19
Volume
1.2M
Market Cap
$257.0M
Day's Low - High
$2.16 - $2.24
52 Week Low - High
$0.88 - $2.28

Cardiol Therapeutics Historical Returns

1 Month Return
+ 54.93 %
3 Month Return
+ 98.2 %
1 Year Return
+ 101.83 %
3 Year Return
+ 126.8 %
5 Year Return
-48.24 %

Cardiol Therapeutics Stock Fundamentals & Key Indicators

Check Cardiol Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$257.0M

EPS (TTM)

-0.3441

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-8.86

Industry PE ratio

1.68

PEG Ratio

-0.24628913572523528

EBITDA

-35.6M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-180.13%

Cardiol Therapeutics Stock Valuation

Track how Cardiol Therapeutics P/E has moved over time to understand its valuation trends.

Cardiol Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-4.07x)

December 31, 2021

Today (-3.36x)

March 31, 2026

Industry (1.68x)

March 31, 2026

Highest (-2.52x)

March 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -3.36x

Cardiol Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cardiol Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$257.0M-48.24%-8.860.00%NA
BUY$20.9B134.45%16.1386.14%NA
HOLD$19.4B15.14%-46.8934.83%2.8400000000000003%
BUY$42.2BNA19.5914.55%129.13%
BUY$31.3B-63.52%12.4770.87%2.76%

Stock Returns calculator for Cardiol Therapeutics Stock including INR - Dollar returns

The Cardiol Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Cardiol Therapeutics investment value today

Current value as on today

₹2,18,508

Returns

₹1,18,508

(+118.51%)

Returns from Cardiol Therapeutics Stock

₹1,02,752 (+102.75%)

Dollar Impact

₹15,756 (+15.76%)

Analyst Recommendation on Cardiol Therapeutics Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Cardiol Therapeutics. Average target price of $8.53

Cardiol Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Cardiol Therapeutics.

What analysts predicted

74.09%UPSIDE

Target Price

$8.53

Current Price

$2.21

Analyzed by

3 Analysts

Target

$8.53

Cardiol Therapeutics target price $8.53, a slight upside of 74.09% compared to current price of $2.21. According to 3 analysts rating.

Indian Investors' Interest in Cardiol Therapeutics Stock

Search interest for Cardiol Therapeutics Stock has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-13% versus previous 30 day period

Cardiol Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
0
-
-
0
-
0
0
Operating Income
-4
-8
-8
-7
-14
-8
-7
-10
-9
-7
EBITDA
-6
-7
-8
-7
-13
-8
-7
-9
-9
-7
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-7
-5
-9
-6
-12
-8
-8
-9
-10
-6
Income Tax Expense
1
-1
0
-
-
-
-
-
-
-
Net Income
-7
-5
-9
-6
-12
-8
-8
-9
-10
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Cardiol Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Dec 2021
Dec 2022
Mar 2024
Mar 2025
Mar 2026
Total Revenue
-
-
-
-
0
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
-
Operating Income
-1
-7
-13
-20
-45
-50
-29
-40
-34
EBITDA
-1
-15
-13
-20
-38
-30
-27
-36
-34
Interest Expense
0
0
0
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-1
-15
-13
-20
-31
-30
-28
-36
-33
Income Tax Expense
-
-
0
0
-6
-19
-
-
-
Net Income
-1
-15
-13
-20
-24
-11
-28
-36
-33
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
100.00%
0.00%
0.00%
0.00%
0.00%

Cardiol Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Mar 2026
Jun 2026
Net Income
-7
-5
-9
-6
-12
-8
-8
-9
-10
-6
Operating Cash Flow
-5
-3
-6
-4
-7
-7
-4
-6
-7
-4
Investing Cash Flow
0
0
0
0
0
0
0
0
0
0
Financing Cash Flow
0
0
0
0
0
0
0
0
13
2
Change in Cash
-4
-4
-6
-4
-8
-7
-5
-6
6
-1

Cardiol Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Dec 2021
Dec 2022
Mar 2024
Mar 2025
Mar 2026
Net Income
-1
-15
-13
-20
-31
-30
-28
-36
-33
Operating Cash Flow
-1
-10
-11
-9
-23
-27
0
-25
-23
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
3
25
2
16
93
0
0
18
15
Change in Cash
2
14
-9
7
69
-24
-24
-4
-9

Mutual Funds that own Cardiol Therapeutics Stock

Check out the Mutual Funds with significant holdings in Cardiol Therapeutics.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.044884%
52435

Global Institutional Holdings in Cardiol Therapeutics

Funds
Holdings
Global X
0.75%

Cardiol Therapeutics News & Key Events

  • img

    Today's Timeline - 13 November

    Thu, 06:15 PM

    -

    Cardiol Therapeutics receives U.S. patent allowance for CardiolRx™ and CRD-38, extending protection until late 2040.

Insights on Cardiol Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, CRDL has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, CRDL has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, CRDL stock has moved up by 54.9%

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
OrganisationCardiol Therapeutics
Headquarters2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. David G. Elsley MBA
E-voting on sharesClick here to vote

Key Management of Cardiol Therapeutics

Name

Title

Mr. John A. Geddes BSCPT, MBA

Vice President of Corporate Development

Mr. David G. Elsley MBA

President, CEO & Director

Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBA

CFO, Corporate Secretary & Director

Mr. Bernard Lim B.Sc.

Chief Operating Officer

Dr. Andrew Warwick Hamer M.D.

Chief Medical Officer and Head of Research & Development

Trevor Burns

Investor Relations

FAQs

What is Cardiol Therapeutics share price today?

Cardiol Therapeutics share price today is $2.21 as on at the close of the market. Cardiol Therapeutics share today touched a day high of $2.24 and a low of $2.16.

What is the 52 week high and 52 week low for Cardiol Therapeutics share?

Cardiol Therapeutics share touched a 52 week high of $2.28 on and a 52 week low of $0.88 on . Cardiol Therapeutics stock price today i.e. is closed at $2.21,which is 2.86% down from its 52 week high and 151.14% up from its 52 week low.

What is Cardiol Therapeutics's market capitalisation today?

Cardiol Therapeutics market capitalisation is $0.00T as on .

How to invest in Cardiol Therapeutics Stock (CRDL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cardiol Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cardiol Therapeutics Shares that will get you 0.6787 shares as per Cardiol Therapeutics share price of $2.21 per share as on September 9, 2026 at 1:29 am IST.

What is the minimum amount required to buy Cardiol Therapeutics Stock (CRDL) from India?

Indian investors can start investing in Cardiol Therapeutics (CRDL) shares with as little as ₹94.8175 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹948.17 in Cardiol Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Cardiol Therapeutics share’s latest price of $2.21 as on September 9, 2026 at 1:29 am IST, you will get 4.5249 shares of Cardiol Therapeutics. Learn more about fractional shares .

What are the returns that Cardiol Therapeutics has given to Indian investors in the last 5 years?

Cardiol Therapeutics stock has given -48.24% share price returns and 28.04% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?